Somewhat Positive News Coverage Somewhat Unlikely to Impact Catalent (CTLT) Share Price
News headlines about Catalent (NASDAQ:CTLT) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalent earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.4540779467023 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern’s scoring:
- Buy stocks analysis: Catalent, Inc. (CTLT) ,Northwest … – Street Observer (press release) (streetobserver.com)
- What 20-Day Moving Average Analysis say about Catalent, Inc. (NYSE:CTLT)? – The Oracle Examiner (oracleexaminer.com)
- Catalent (CTLT) Prices 6.395M Common Share Offering at $39.10/Sh – StreetInsider.com (streetinsider.com)
- Catalent, Inc. Announces Pricing of Public Offering of Common Stock to Fund Part of its Acquisition of Cook Pharmica (finance.yahoo.com)
- CATALENT, INC. (NYSE:CTLT) Files An 8-K Other Events (4-traders.com)
A number of analysts have recently issued reports on the company. BidaskClub lowered Catalent from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research raised Catalent from a “sell” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Tuesday, July 4th. Bank of America Corporation reissued a “buy” rating and issued a $38.00 price objective (up from $37.00) on shares of Catalent in a research note on Friday, July 21st. Piper Jaffray Companies reissued a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research note on Tuesday, August 29th. Finally, J P Morgan Chase & Co restated a “buy” rating and issued a $40.00 price objective on shares of Catalent in a report on Tuesday, August 29th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $38.64.
Catalent (CTLT) opened at 41.29 on Tuesday. The firm’s 50-day moving average price is $38.66 and its 200-day moving average price is $34.48. Catalent has a 1-year low of $21.83 and a 1-year high of $42.22. The firm has a market cap of $5.17 billion and a price-to-earnings ratio of 47.46.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 28th. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The company had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. During the same quarter last year, the business posted $0.52 earnings per share. Catalent’s revenue was up 15.9% compared to the same quarter last year. On average, equities research analysts anticipate that Catalent will post $1.62 earnings per share for the current year.
In related news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-catalent-ctlt-share-price/1604252.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.